Rigel Pharma (RIGL) Reports In-Line Q2 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Rigel Pharma (RIGL) Reports In-Line Q2 EPS

Rigel Announces Second Quarter 2018 Financial Results and Provides Company Update

August 8, 2018 4:08 PM EDT

SOUTH SAN FRANCISCO, Calif., Aug. 8, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today reported financial results for the second quarter of 2018 and provided an update on the commercial launch of TAVALISSE and the clinical development pipeline.

 Recent Highlights:

On May 29, Rigel launched TAVALISSE (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The TAVALISSE commercial team, at over 50 employees strong, is fully deployed and supporting ITP-prescribing physicians across the United... More